文献速递皮肤肿瘤

单发与多发原发性皮肤黑色素瘤患者的生存比较

Comparison of Survival Between Patients With Single vs Multiple Primary Cutaneous Melanomas.
PubMed 文献 · JAMA Dermatol · 2019-01-01

该回顾性人群队列研究纳入2000至2014年荷兰56 929例成人原发性侵袭性皮肤黑色素瘤患者,中位随访75.1个月,比较单发与多发原发性黑色素瘤的总生存。多发患者总生存显著更差(HR 1.31;95%CI 1.20-1.42;P<.001),第二原发瘤Breslow厚度较第一原发瘤显著下降。

要点

  • 多发原发性黑色素瘤患者总生存显著差于单发患者(HR 1.31;95%CI 1.20-1.42)。
  • 第二原发黑色素瘤Breslow厚度中位数较第一原发瘤显著下降(0.90 mm vs 0.65 mm,P<.001)。
  • 36.8%的第二原发瘤在随访第一年内发现,27.3%在5年后发现。

核心结论

  • 多发原发性黑色素瘤患者的总生存显著差于单发原发性黑色素瘤患者(HR 1.31;95%CI 1.20-1.42;P<.001)。
  • 第二原发黑色素瘤的Breslow厚度较第一原发瘤显著下降,提示更严格随访策略可能必要。

研究设计与样本

  • 回顾性、人群为基础的队列研究,数据来自荷兰PALGA全国组织病理学与细胞病理学网络登记及荷兰癌症登记。
  • 纳入2000年1月1日至2014年12月31日荷兰成人组织学证实的原发性侵袭性皮肤黑色素瘤患者,中位随访75.1个月。
  • 共纳入56 929例患者,其中女性31 916例(56.1%),平均(SD)年龄56.4(16.2)岁;单发黑色素瘤54 645例,2284例患者中共4967个多发原发性黑色素瘤。
  • 采用含时变协变量的多因素Cox模型评估单发与多发原发性黑色素瘤患者的总生存。

主要发现

  • 第二原发黑色素瘤Breslow厚度中位数从第一原发瘤的0.90 mm(IQR 0.55-1.70 mm)降至0.65 mm(IQR 0.45-1.10 mm)(P<.001)。
  • 2284例多发患者中,第二原发瘤T分期更高者370例(16.2%),相同者1112例(48.7%),更低者802例(35.1%)。
  • 2284个第二原发黑色素瘤中,841个(36.8%)在随访第一年内发现,624个(27.3%)在5年后发现;按黑色素瘤分期分层后比例无变化。
  • 多发原发性黑色素瘤患者总生存较单发患者更差(HR 1.31;95%CI 1.20-1.42;P<.001)。

临床怎么用

  • 对多发原发性黑色素瘤患者应考虑更严格的随访策略。
  • 随访中需关注第二原发黑色素瘤,尤其随访第一年内及5年后。

局限性

  • 本研究为回顾性、人群为基础队列研究,可能存在回顾性设计固有局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Melanoma is one of the most rapidly increasing forms of cancer worldwide. Most studies about survival among patients with melanoma consider only the primary tumor and disregard the potential effect of multiple primary tumors. A better understanding of the prognosis of patients with multiple primary melanoma is important for patient counselling and follow-up strategies. OBJECTIVE: To describe the epidemiologic features of multiple primary melanoma in patients from the Netherlands. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, population-based cohort study included adults with histologically proven, primary, invasive cutaneous melanoma in the Netherlands between January 1, 2000, and December 31, 2014, with a median follow-up of 75.1 months, using data from PALGA, the Dutch Nationwide Network and Registry of Histopathology and Cytopathology. Follow-up data were retrieved from the Netherlands Cancer Registry. Statistical analysis was performed from August 1, 2018, to September 3, 2018. MAIN OUTCOMES AND MEASURES: A multivariable Cox model with a time-varying covariate was performed to assess overall survival between patients with a single primary melanoma vs those with multiple primary melanomas. Secondary outcomes included incidence of multiple primary melanoma, differences in Breslow thickness, and time between first and second multiple primary melanoma. RESULTS: Of the 56 929 study patients, 31 916 (56.1%) were female, with a mean (SD) age of 56.4 (16.2) years. A total of 54 645 single primary melanomas and 4967 multiple primary melanomas in 2284 patients were included. The median Breslow thickness decreased from 0.90 mm (interquartile range, 0.55-1.70 mm) for the first melanoma to 0.65 mm (interquartile range, 0.45-1.10 mm) for the second melanoma (P < .001). For their second melanoma, 370 patients (16.2%) had a higher T stage, 1112 (48.7%) had the same T stage, and 802 (35.1%) had a lower T stage. In addition, 841 of 2284 second melanomas (36.8%) in patients with multiple primary melanomas were found during the first year of follow-up, whereas 624 of 2284 (27.3%) were found after 5 years of follow-up. These proportions did not vary when stratified for melanoma stage. Worse overall survival was seen among patients with multiple primary melanomas compared with patients with a single primary melanoma (hazard ratio, 1.31; 95% CI, 1.20-1.42; P < .001). CONCLUSIONS AND RELEVANCE: A significant decrease in Breslow thickness between the first and second multiple primary melanoma was found, and overall survival among patients with multiple primary melanomas was significantly worse than that among patients with a single primary melanoma. These findings suggest that more strict follow-up strategies may be warranted for patients with multiple primary melanomas.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. El Sharouni MA, Witkamp AJ, Sigurdsson V, et al. Comparison of Survival Between Patients With Single vs Multiple Primary Cutaneous Melanomas. JAMA Dermatol. 2019. PMID: 31241717. doi:10.1001/jamadermatol.2019.1134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。